SciSparc Ltd.

SPRC ·Healthcare, Drug Manufacturers - General, Israel
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022
Revenue $1.3M $2.9M $1.3M
Cost of Revenue $800.0K $683.0K $322.0K
Gross Profit $506.0K $2.2M $1.0M
Gross Margin 38.7% 76.3% 76.1%
Operating Expenses
Research & Development — — —
SG&A Expense — — —
Operating Income $-7.3M $-6.8M $-8.3M
Operating Margin -560.2% -236.7% -615.2%
Interest Expense — — —
Pretax Income $-7.5M $-5.9M $-2.6M
Income Tax Expense $-14.0K $22.0K $14.0K
Net Income $-6.3M $-5.1M $-2.6M
Net Margin -481.2% -177.9% -192.4%
EPS (Basic) $1.28 $14.43 $14.82
EPS (Diluted) $1.28 $14.43 $14.82
Shares Outstanding (Basic) 10.8M 706.7K 6.8M
Shares Outstanding (Diluted) 10.8M 706.7K 6.8M
Dividends Per Share — — —